Enlivex Therapeutics Ltd. (ENLV.TA)
ILA 433.2
(5.2%)
ILA 433.2
(5.2%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 30.63 Million | 25.79 Million | 19.28 Million | 9.78 Million | 8.61 Million | 5.29 Million |
| Selling, General and Administrative Expenses | 6.13 Million | 6.7 Million | 6.24 Million | 3.6 Million | 2.75 Million | 937 Thousand |
| Research and Development Expenses | 19.23 Million | 18.69 Million | 12.88 Million | 6.08 Million | 5.72 Million | 4.25 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 30.63 Million | 25.79 Million | 19.28 Million | 9.78 Million | 8.61 Million | 5.29 Million |
| Operating Income | -25.15 Million | -25.79 Million | -19.28 Million | -9.78 Million | -8.61 Million | -5.29 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | 5.26 Million | -4.82 Million | 2.03 Million | 765 Thousand | -1.05 Million |
| Earnings before Tax | -29.06 Million | -31.06 Million | -14.46 Million | -11.82 Million | -9.38 Million | -4.24 Million |
| Net Income | -29.06 Million | -31.06 Million | -14.46 Million | -11.82 Million | -9.38 Million | -4.24 Million |
| Earnings Per Share Basic | -1.56 | -1.69 | -0.81 | -0.90 | -1.08 | -1.21 |
| Earnings Per Share Diluted | -1.56 | -1.69 | -0.81 | -0.90 | -1.08 | -1.21 |
| Weighted Average Shares Outstanding | 18.57 Million | 18.39 Million | 17.85 Million | 13.16 Million | 8.64 Million | 3.5 Million |
| Weighted Average Shares Outstanding (Diluted) | 18.57 Million | 18.39 Million | 17.85 Million | 13.16 Million | 8.64 Million | 3.5 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -24.31 Million | -18.93 Million | -23.77 Million | -7.24 Million | -7.41 Million | -6.1 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 2.98 Million | 3.95 Million | 6.09 Million | 30.63 Million | 5.62 Million | 6.64 Million |
| Selling, General and Administrative Expenses | 987 Thousand | 1.09 Million | 733 Thousand | - | 1.27 Million | 1.61 Million |
| Research and Development Expenses | 1.99 Million | 2.85 Million | 4.45 Million | - | 4.34 Million | 5.03 Million |
| Other Expenses | - | - | - | - | -335 Thousand | -143 Thousand |
| Cost and Expenses | 2.98 Million | 3.95 Million | 6.09 Million | 30.63 Million | 5.62 Million | 6.64 Million |
| Operating Income | -2.98 Million | -4.15 Million | -10.33 Million | -25.15 Million | -5.62 Million | -6.64 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | 190 Thousand | -1.55 Million | - | 253.58 Thousand | 89.91 Thousand |
| Earnings before Tax | -3.09 Million | -4.14 Million | -9.09 Million | -29.06 Million | -5.96 Million | -6.79 Million |
| Net Income | -3.09 Million | -4.14 Million | -9.09 Million | -29.06 Million | -5.96 Million | -6.79 Million |
| Earnings Per Share Basic | -0.16 | -0.22 | -0.49 | - | -0.32 | -0.37 |
| Earnings Per Share Diluted | -0.16 | -0.22 | -0.49 | - | -0.32 | -0.37 |
| Weighted Average Shares Outstanding | 19.54 Million | 18.72 Million | 18.59 Million | 18.57 Million | 18.59 Million | 18.58 Million |
| Weighted Average Shares Outstanding (Diluted) | 19.54 Million | 18.72 Million | 18.59 Million | 18.57 Million | 18.59 Million | 18.58 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -2.82 Million | -3.56 Million | -5.89 Million | - | -5.41 Million | -6.43 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
ACAD
603922
6160
SLRRF
603876
002343